Citations

Mayo Clinic

Showing 10 of 108572 citations.

Digital Interventions and Their Unexpected Outcomes – Time for Digitalovigilance?
López–Campos, Guillermo , Martín-Sánchez, Fernando , Petersen, Carolyn , Petersen, Carolyn , Gabarrón, Elia , Merolli, Mark , Denecke, Kerstin

Studies in Health Technology and Informatics | January 25, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3233/shti231011 | PMID 38269849 Get It

The application of digital interventions in healthcare beyond research has been translated in the development of software as a medical device. Along with corresponding regulations for medical devices, there is a need for assessing adverse events to conduct post-market surveillance and to appropriately label digital health interventions to ensure proper use and patient safety. To date unexpected consequences of digital health interventions are neglected or ignored, or at least remain undescribed in literature. This paper is intended to raise awareness across the research community about these upcoming challenges. We recommend that - together with developing a new research field of digitalovigilance - a systematic assessment and monitoring of adverse events and unexpected interactions be included in clinical trials, along with the reporting of such events and the conduct of meta-analyses on critical aspects.
Unscheduled Emergency Department Revisits Within 48 Hours of Discharge
Ratti, María Florencia Grande , Martingano, Ignacio , Otero, Paula Daniela, Otero, Carlos , Rubin, Luciana, Luna, Daniel , Esteban, Jorge Ariel, Pedretti, Ana Soledad , Rodríguez, María de la Paz , Cid, Micaela Sanchez Del, Martínez, Bernardo , Farina, Juan María, Farina, Juan M.

Studies in Health Technology and Informatics | January 25, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3233/shti230976 | PMID 38269814 Get It

This study aimed to analyze early revisits (within 48 hours of discharge) in an Emergency Department. Among the 178,295 visits, 11,686 were revisits, resulting in a rate of 6.55% (95%CI 6.43-6.67). A total of 1,410 revisits required hospitalization, and 252 were due to preventable errors (17.87%). These errors were mainly related to an inadequate therapeutic plan at discharge (47.22%), an incomplete diagnostic process (29.37%), and misdiagnoses (13.10%). These findings represent a technology-enabled clinical audit tool. Electronic Healthcare Records have the potential to: provide quality metrics of hospital performance, help to keep revisit rates updated (assessment through a real-time dashboard), and improve clinical management (by transparency initiatives about errors, and a supportive learning environment regarding lessons learned).
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management
Tefferi, Ayalew , Vannucchi, Alessandro M. , Barbui, Tiziano , Vannucchi, Alessandro M

American Journal of Hematology | January 25, 2024 | Volume: 99 | Issue: 4 | Pages: 697-718

10.1002/ajh.27216 | PMID 38269572 Get It

AbstractOverviewEssential thrombocythemia is a Janus kinase 2 (JAK2) mutation‐prevalent myeloproliferative neoplasm characterized by clonal thrombocytosis; clinical course is often indolent but might be interrupted by thrombotic or hemorrhagic complications, microcirculatory symptoms (e.g., headaches, lightheadedness, and acral paresthesias), and, less frequently, by disease transformation into myelofibrosis (MF) or acute myeloid leukemia.DiagnosisIn addition to thrombocytosis (platelets ≥450 × 109/L), formal diagnosis requires the exclusion of other myeloid neoplasms, including prefibrotic MF, polycythemia vera, chronic myeloid leukemia, and myelodysplastic syndromes with ring sideroblasts and thrombocytosis. Bone marrow morphology typically shows increased number of mature‐appearing megakaryocytes distributed in loose clusters.Genetics: Approximately 80% of patients express myeloproliferative neoplasm driver mutations (JAK2, CALR, MPL), in a mutually exclusive manner; in addition, about 50% harbor other mutations, the most frequent being TET2 (9%–11%), ASXL1 (7%–20%), DNMT3A (7%), and SF3B1 (5%). Abnormal karyotype is seen in <10% of patients and includes +9/20q−/13q‐.Survival and PrognosisLife expectancy is less than that of the control population. Median survival is approximately 18 years but exceeds >35 years in younger patients. The triple A survival risk model, based on Age, Absolute neutrophil count, and Absolute lymphocyte count, effectively delineates high‐, intermediate‐1‐, intermediate‐2‐, and low‐risk disease with corresponding median survivals of 8, 14, 21, and 47 years.Risk Factors for ThrombosisFour risk categories are considered: very low (age ≤60 years, no thrombosis history, JAK2 wild‐type), low (same as very low but JAK2 mutation present), intermediate (same as low but age >60 years), and high (thrombosis history or age >60 years with JAK2 mutation).Mutations and PrognosisMPL and CALR‐1 mutations have been associated with increased risk of MF transformation; spliceosome with inferior overall and MF‐free survival; TP53 with leukemic transformation, and JAK2V617F with thrombosis. Leukemic transformation rate at 10 years is <1% but might be higher in JAK2‐mutated patients with extreme thrombocytosis and those with abnormal karyotype.TreatmentThe main goal of therapy is to prevent thrombosis. In this regard, once‐daily low‐dose aspirin is advised for all patients and twice daily for low‐risk disease. Cytoreductive therapy is advised for high‐risk and optional for intermediate‐risk disease. First‐line cytoreductive drugs of choice are hydroxyurea and pegylated interferon‐α and second‐line busulfan.Additional ContentThe current review includes specific treatment strategies in the context of extreme thrombocytosis, pregnancy, splanchnic vein thrombosis, perioperative care, and post‐essential thrombocythemia MF, as well as new investigational drugs.
Health Equity and Policy Considerations for Pediatric and Adult Congenital Heart Disease Care among Minoritized Populations in the United States
Allen, Kiona Y. , Baker‐Smith, Carissa M. , Bravo‐Jaimes, Katia , Burns, Joseph, Cherestal, Bianca , Deen, Jason F. , Hills, Brittney K. , Huang, Jennifer , Santamaria, Ramiro W. Lizano, Lodeiro, Carlos A., Melo, Valentina, Moreno, Jasmine , Gallegos, Flora Nuñez , Onugha, Harris U, Pastor, Tony A., Wallace, Michelle C. , Ansah, Deidra , Allen, Kiona Y , Baker-Smith, Carissa M , Bravo-Jaimes, Katia , Cherestal, Bianca , Hills, Brittany K , Lopez, Keila N. , Pastor, Tony A.

Journal of Cardiovascular Development and Disease | January 25, 2024 | Volume: 11 | Issue: 2 | Pages: 36

10.3390/jcdd11020036 | PMID 38392250 Get It

Achieving health equity in populations with congenital heart disease (CHD) requires recognizing existing disparities throughout the lifespan that negatively and disproportionately impact specific groups of individuals. These disparities occur at individual, institutional, or system levels and often result in increased morbidity and mortality for marginalized or racially minoritized populations (population subgroups (e.g., ethnic, racial, social, religious) with differential power compared to those deemed to hold the majority power in the population). Creating actionable strategies and solutions to address these health disparities in patients with CHD requires critically examining multilevel factors and health policies that continue to drive health inequities, including varying social determinants of health (SDOH), systemic inequities, and structural racism. In this comprehensive review article, we focus on health equity solutions and health policy considerations for minoritized and marginalized populations with CHD throughout their lifespan in the United States. We review unique challenges that these populations may face and strategies for mitigating disparities in lifelong CHD care. We assess ways to deliver culturally competent CHD care and to help lower-health-literacy populations navigate CHD care. Finally, we review system-level health policies that impact reimbursement and research funding, as well as institutional policies that impact leadership diversity and representation in the workforce.
Impact of Program Changes Including Telemedicine and Telephonic Care During the COVID-19 Pandemic in Preventing 30-Day Hospital Readmission for Patients in a Care Transitions Program
Takahashi, Paul Y. , Ramar, Priya , Canning, Rachel, Hanson, Gregory J. , Baumbach, Lori J., Chandra, Anupam , Philpot, Lindsey M. , Thorsteinsdottir, Bjorg , Philpot, Lindsey M , Takahashi, Paul , McCoy, Rozalina G. , Hanson, Gregory J.

Journal of Primary Care & Community Health | January 25, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241226547 | PMID 38270059 Get It

Introduction/Objectives: To describe health outcomes of older adults enrolled in the Mayo Clinic Care Transitions (MCCT) program before and during the COVID-19 pandemic compared to unenrolled patients. Methods: We conducted a retrospective cohort study of adults (age >60 years) in the MCCT program compared to a usual care control group from January 1, 2019, to September 20, 2022. The MCCT program involved a home, telephonic, or telemedicine visit by an advanced care provider. Outcomes were 30- and 180-day hospital readmissions, emergency department (ED) visit, and mortality. We performed a subgroup analysis after March 1, 2020 (during the pandemic). We analyzed data with Cox proportional hazards regression models and hazard ratios (HRs) with 95% CIs. Results: Of the 1,012 patients total, 354 were in the MCCT program and 658 were in the usual care group with a mean (SD) age of 81.1 (9.1) years overall. Thirty-day readmission was 16.9% (60 of 354) for MCCT patients and 14.7% (97 of 658) for usual care patients (HR, 1.24; 95% CI, 0.88-1.75). During the pandemic, the 30-day readmission rate was 15.1% (28 of 186) for MCCT patients and 14.9% (68 of 455) for usual care patients (HR, 1.20; 95% CI, 0.75-1.91). There was no difference between groups for 180-day hospitalization, 30- or 180-day ED visit, and 30- or 180-day mortality. Conclusions: Numerous factors involving patients, providers, and health care delivery systems during the pandemic most likely contributed to these findings.
Clinical Implementation of an AI Early Warning System Algorithm: Lessons Learned
Meehan, Anne M. , Core, Marcia A., Ross, Jared M., Rahman, Parvez, Caraballo, Pedro J. , Rahman, Parvez A, Caraballo, Pedro J , Borah, Bijan J.

Studies in Health Technology and Informatics | January 25, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3233/shti231202 | PMID 38269654 Get It

The Deterioration Index (DI) is an automatic early warning system that utilizes a machine learning algorithm integrated into the electronic health record and was implemented to improve risk stratification of inpatients. Our pilot implementation showed superior diagnostic accuracy than standard care. A score >60 had a specificity of 88.5% and a sensitivity of 59.8% (PPV 0.1758, NPP 0.9817). However, acceptance in the clinical workflow was divided; nurses preferred standard care, while providers found it helpful.
Pulmonary hypertension patient perspectives toward pulmonary rehabilitation
Bailey, M. , DuBrock, Hilary M. , Bailey, Morgan , DuBrock, Hilary M

Pulmonary Circulation | January 25, 2024 | Volume: 14 | Issue: 1 | Pages: No page available

10.1002/pul2.12338 | PMID 38274561 Get It

AbstractPulmonary rehabilitation (PR) is a supervised exercise program for patients with chronic lung disease. Among patients with pulmonary hypertension (PH), PR has been shown to improve both quality of life and exercise capacity. The purpose of this study was to assess the prevalence of PR participation among PH patients, patient perspectives regarding PR, and to identify potential barriers to PR participation. We performed a cross‐sectional survey of patients with self‐reported PH who attended the Pulmonary Hypertension Association (PHA) conference in June 2022 in Atlanta, Georgia, and patients within the PHA listserv. A total of 429 participants completed the survey and were enrolled in the study. The average age of participants was 61 ± 14 years with 83% of participants identifying as female, 51% of patients self‐reported as having group 1 PH. Among patients who completed the survey, 41% had previously attended a PR program. Of those who had completed a PR program, 83% reported being satisfied or very satisfied with the program and 86% reported that they would recommend PR to other PH patients. After completion of a PR program, 76% of patients reported an improvement in their quality of life and 88% reported improvement in exercise capacity. Among the patients who had not previously participated in PR (n = 254), 63% reported an interest in participation while 64% cited a lack of discussion from their treatment team as the primary reason for the lack of PR participation. Limitations of the study include sampling and response bias. According to this cross‐sectional survey, the majority of PH patients who have participated in PR report improvement in both quality of life and exercise capacity and would recommend PR to other PH patients. The majority of PH patients who have not participated in PR were interested in participation and cited a lack of discussion with their treatment team as one of the primary reasons for the lack of participation. PR is associated with self‐reported improvements in quality of life and exercise capacity but remains underutilized among patients with PH.
Clinical Images: Sarcoidosis with concomitant aortitis and coronary arteritis
Kaymakci, Mahmut , Araoz, Philip A. , Koster, Matthew J. , Elfishawi, Mohanad M, Kaymakci, Mahmut S , Koster, Matthew J , Elfishawi, Mohanad , Lo, Ying‐Chun , Warrington, Kenneth J.

ACR Open Rheumatology | January 25, 2024 | Volume: 6 | Issue: 4 | Pages: 201-202

10.1002/acr2.11631 | PMID 38269608 Get It

MCC950 Attenuates Microglial NLRP3-Mediated Chronic Neuroinflammation and Memory Impairment in a Rat Model of Repeated Low-Level Blast Exposure
Murray, Kathleen E. , Murray, Kathleen E., Rao, Kakulavarapu V. Rama , Pfister, Bryan J. , Citron, Bruce A. , Chandra, Namas , Ravula, Arun Reddy, Ravula, Arun Reddy , Murray, Kathleen E.

Journal of Neurotrauma | January 25, 2024 | Volume: 41 | Issue: 11-12 | Pages: 1450-1468

10.1089/neu.2023.0444 | PMID 38269433 Get It

Blast-induced traumatic brain injury is typically regarded as a signature medical concern for military personnel who are exposed to explosive devices in active combat zones. However, soldiers as well as law enforcement personnel may be repeatedly exposed to low-level blasts during training sessions with heavy weaponries as part of combat readiness. Service personnel who sustain neurotrauma from repeated low-level blast (rLLB) exposure do not display overt pathological symptoms immediately but rather develop mild symptoms including cognitive impairments, attention deficits, mood changes, irritability, and sleep disturbances over time. Recently, we developed a rat model of rLLB by applying controlled low-level blast pressures (≤ 70 kPa) repeated five times successively to mimic the pressures experienced by service members. Using this model, we assessed anxiety-like symptoms, motor coordination, and short-term memory as a function of time. We also investigated the role of the NLRP3 inflammasome, a complex involved in chronic microglial activation and pro-inflammatory cytokine interleukin (IL)-1β release, in rLLB-induced neuroinflammation. NLRP3 and caspase-1 protein expression, microglial activation, and IL-1β release were examined as factors likely contributing to these neurobehavioral changes. Animals exposed to rLLB displayed acute and chronic short-term memory impairments and chronic anxiety-like symptoms accompanied by increased microglial activation, NLRP3 expression, and IL-1β release. Treatment with MCC950, an NLRP3 inflammasome complex inhibitor, suppressed microglial activation, reduced NLRP3 expression and IL-1β release, and improved short-term memory deficits after rLLB exposure. Collectively, this study demonstrates that rLLB induces chronic neurobehavioral and neuropathological changes by increasing NLRP3 inflammasome protein expression followed by cytokine IL-1β release.
EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor
Sprinzen, Lisa , Garcia, Franklin , Mela, Angeliki , Lei, Liang, Humala, Nelson, Manier, Lisa, Caprioli, Richard M. , Quiñones‐Hinojosa, Alfredo , Canoll, Peter , Lei, Liang, Upadhyayula, Pavan S. , Mahajan, Aayushi , Casaccia, Patrizia

Cells | January 25, 2024 | Volume: 13 | Issue: 3 | Pages: 219

10.3390/cells13030219 | PMID 38334611 Get It

Isocitrate Dehydrogenase-1 (IDH1) is commonly mutated in lower-grade diffuse gliomas. The IDH1R132H mutation is an important diagnostic tool for tumor diagnosis and prognosis; however, its role in glioma development, and its impact on response to therapy, is not fully understood. We developed a murine model of proneural IDH1R132H-mutated glioma that shows elevated production of 2-hydroxyglutarate (2-HG) and increased trimethylation of lysine residue K27 on histone H3 (H3K27me3) compared to IDH1 wild-type tumors. We found that using Tazemetostat to inhibit the methyltransferase for H3K27, Enhancer of Zeste 2 (EZH2), reduced H3K27me3 levels and increased acetylation on H3K27. We also found that, although the histone deacetylase inhibitor (HDACi) Panobinostat was less cytotoxic in IDH1R132H-mutated cells (either isolated from murine glioma or oligodendrocyte progenitor cells infected in vitro with a retrovirus expressing IDH1R132H) compared to IDH1-wild-type cells, combination treatment with Tazemetostat is synergistic in both mutant and wild-type models. These findings indicate a novel therapeutic strategy for IDH1-mutated gliomas that targets the specific epigenetic alteration in these tumors.